Derazantinib; ARQ-087

Izina ryimiti:

(6R) -6- (2-fluorophenyl) -5,6-dihydro-N- [3- [2 -

Kode ya SMILES:

COCCNCCC1 = CC (NC2 = NC = C3C [C @@ H] (C4 = CC = CC = C4F) C5 = CC = CC = C5C3 = N2) = CC = C1

InChi Code:

InChI = 1S / C29H29FN4O ​​/ c1-35-16-15-31-14-13-20-7-6-8-22 (17-20) 33-29-32-19-21-18-26 (24- 10-4-5-12-27 (24) 30) 23-9-2-3-11-25 (23) 28 (21) 34-29 / h2-12,17,19,26,31H, 13- 16,18H2,1H3, (H, 32,33,34) / t26- / m1 / s1

InChi Urufunguzo:

KPJDVVCDVBFRMU-AREMUKBSSA-N

Ijambo ryibanze:

Derazantinib, ARQ-087, ARQ087, ARQ 087, 1234356-69-4

Gukemura:Gukemura muri DMSO

Ububiko:0 - 4 ° C mugihe gito (iminsi kugeza ibyumweru), cyangwa -20 ° C mugihe kirekire (amezi).

Ibisobanuro:

Derazantinib, izwi kandi ku izina rya ARQ-087, ni bioavailable yo mu kanwa ikumira fibroblast growth factor reseptor (FGFR) ifite ibikorwa bya antineoplastique. Inhibitor ya FGFR ARQ 087 ihuza kandi ikabuza cyane ibikorwa byubwoko bwa FGFR 1, 2 na 3. Ibi bishobora kuviramo guhagarika inzira yo kwanduza ibimenyetso bya FGFR yifashishijwe, gukwirakwiza kanseri yibibyimba, ibibyimba angiogenezi hamwe nimpfu ziterwa na selile yibibyimba bya FGFR-bikabije . FGFR, reseptor tyrosine kinase, igenzurwa mubwoko bwinshi bwibibyimba kandi igira uruhare runini mugukwirakwiza kanseri yibibyimba, gutandukana, angiogenezi no kubaho.

Intego: FGFR